Illumina TruSight Oncology 500 ctDNA
The Illumina TruSight Oncology 500 circulating tumour DNA (ctDNA) assay is an NGS-based assay that enables comprehensive genomic profiling to assess multiple variant types in 523 cancer-related genes from cell-free DNA (cfDNA). This assay features the same DNA content as the TruSight Oncology 500 solid tumour assay for detection of single nucleotide variants (SNVs), indels, copy number variants (CNVs), DNA fusions, tumour mutational burden (TMB), and microsatellite instability (MSI) from plasma samples.
In addition, the DRAGEN Bio-IT Platform offers speed and accuracy to detect variants detections through its ultra-rapid variant calling algorithm.
Download the technical sheet to find out more.View Resource
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.